About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Dexmedetomidine in Seizure Patients

NCT01116700·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of California, San Francisco

Age

18–65

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Age 18-65, BMI 20-25 kg/m2
Anticonvulsant Group: Diagnosis of seizure disorder taking carbamazepine or phenytoin for a minimum of 2 weeks
Control Group: Healthy volunteers taking no medications

You may not be if

Positive urine pregnancy test or lactating
History of allergy to dexmedetomidine or alpha -2 agonists
History of liver, renal or thyroid disease
History of cardiovascular disease including history of arrhythmia or congestive heart failure
History of drug or alcohol abuse

The record

StatusCompleted

PhasePhase 1

Taking part16

StartedDec 2010

UpdatedAug 9, 2013

Conditions

Seizure Disorders

Where1

University of California San Francisco
San Francisco, California, United States

Clareo Health | Dexmedetomidine in Seizure Patients